The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy – the TABANETOC trial: study protocol for a randomized clinical multicenter trial
DOI:
https://doi.org/10.2340/1651-226X.2024.40207Keywords:
clinical trial, neoadjuvant chemotherapy, ovarian cancer, tinzaparinAbstract
Background: Tinzaparin, a low-molecular weight heparin (LMWH), has shown anti-neoplastic properties in animal models and in in vitro studies of human cancer cell lines. The reduction of CA-125 levels during neoadjuvant chemotherapy (NACT) in patients with epithelial ovarian cancer (EOC) co-varies with the prognosis; the larger the decrease in CA-125, the better the prognosis.
Purpose: This study aims to evaluate the potential anti-neoplastic effects of tinzaparin by investigating changes in serum CA-125 levels in advanced EOC patients who receive NACT.
Material and methods: This is an open randomized multicenter pilot trial. Forty patients with EOC selected to receive NACT will be randomized 1:1 to receive daily addition of tinzaparin or no tinzaparin. The processing and treatment of the patients will otherwise follow the recommendations in the Swedish National Guidelines for Ovarian Cancer. Before every cycle of chemotherapy, preoperatively, and 3 weeks after the last cycle of chemotherapy, a panel of biomarkers, including CA-125, will be measured.
Patients: Inclusion criteria are women aged 18 years or older, World Health Organization performance status 0–1, histologically confirmed high-grade serous, endometrioid or clear cell EOC, International Federation of Gynecology and Obstetrics (FIGO) stages III-IV. In addition, a CA-125 level of ≥ 250 kIE/L at diagnosis. Exclusion criteria are contraindications to LMWH, ongoing or recent treatment with unfractionated heparin, LMWH, warfarin or non-vitamin K antagonist oral anticoagulants.
Interpretation: This study will make an important contribution to the knowledge of the anti-neoplastic effects of tinzaparin in EOC patients and may thus guide the planning of a future study on the impact of tinzaparin on survival in EOC.
Downloads
References
Regionala Cancercentrum i Samverkan. Svenska kvalitetsregistret för gynekologisk cancer [Internet]. In Swedish [cited 2024 Jan 18]. Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/gynekologi/kvalitetsregister/
Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–47.
https://doi.org/10.1016/j.ajpath.2015.11.011 DOI: https://doi.org/10.1016/j.ajpath.2015.11.011
Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188503.
https://doi.org/10.1016/j.bbcan.2021.188503 DOI: https://doi.org/10.1016/j.bbcan.2021.188503
Wang Q, Feng X, Liu X, Zhu S. Prognostic value of elevated pre-treatment serum CA-125 in epithelial ovarian cancer: a meta-analysis. Front Oncol. 2022;12:868061.
https://doi.org/10.3389/fonc.2022.868061 DOI: https://doi.org/10.3389/fonc.2022.868061
Kessous R, Wissing MD, Piedimonte S, Abitbol J, Kogan L, Laskov I, et al. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. Acta Obstet Gynecol Scand. 2020;99(7):933–40.
https://doi.org/10.1111/aogs.13814 DOI: https://doi.org/10.1111/aogs.13814
Lee M, Chang MY, Yoo H, Lee KE, Chay DB, Cho H, et al. Clinical significance of CA125 level after the first cycle of chemotherapy on survival of patients with advanced ovarian cancer. Yonsei Med J. 2016;57(3):580–7.
https://doi.org/10.3349/ymj.2016.57.3.580 DOI: https://doi.org/10.3349/ymj.2016.57.3.580
Chen Y, Zhang L, Liu WX, Liu XY. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in Chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2015;16(3):933–9.
https://doi.org/10.7314/APJCP.2015.16.3.933 DOI: https://doi.org/10.7314/APJCP.2015.16.3.933
Ayhan A, Günakan E, Alyazıcı İ, Haberal N, Altundağ Ö, Dursun P. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296(5):989–95.
https://doi.org/10.1007/s00404-017-4511-9 DOI: https://doi.org/10.1007/s00404-017-4511-9
Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw. 2013;24(3):106–13.
https://doi.org/10.1684/ecn.2013.0340 DOI: https://doi.org/10.1684/ecn.2013.0340
Sanna E, Tanca L, Cherchi C, Gramignano G, Oppi S, Chiai MG, et al. Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer. Diagnostics (Basel). 2021;20;11(7):1298.
https://doi.org/10.3390/diagnostics11071298 DOI: https://doi.org/10.3390/diagnostics11071298
Dimakakos EP, Vathiotis I, Syrigos K. The role of tinzaparin in oncology. Clin Appl Thromb Hemost. 2018;24(5):697–707.
https://doi.org/10.1177/1076029617729215 DOI: https://doi.org/10.1177/1076029617729215
Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-Inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015;2015:507151.
https://doi.org/10.1155/2015/507151 DOI: https://doi.org/10.1155/2015/507151
Bruno V, Svensson-Arvelund J, Rubér M, Berg G, Piccione E, Jenmalm MC, et al. Effects of low molecular weight heparin on the polarization and cytokine profile of macrophages and T helper cells in vitro. Sci Rep. 2018;8(1):4166.
https://doi.org/10.1038/s41598-018-22418-2 DOI: https://doi.org/10.1038/s41598-018-22418-2
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
https://doi.org/10.1016/j.cell.2011.02.013 DOI: https://doi.org/10.1016/j.cell.2011.02.013
Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012;31(1–2):143–62.
https://doi.org/10.1007/s10555-011-9337-5 DOI: https://doi.org/10.1007/s10555-011-9337-5
Mitsis M, Koliou P, Bali C, Ntounousi E, Tatsis V, Nousias V, et al. In surgical colon cancer patients extended-duration thromboprophylaxis (30 days) with the highest dose of tinzaparin (4,500 IU s.c./q.d.) normalizes the postoperative VEGF levels. J Cancer. 2017;25;8(15):2899–906.
https://doi.org/10.7150/jca.20107 DOI: https://doi.org/10.7150/jca.20107
Pfankuchen DB, Stölting DP, Schlesinger M, Royer HD, Bendas G. Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells. Biochem Pharmacol. 2015;15;97(2):147–57.
https://doi.org/10.1016/j.bcp.2015.07.013 DOI: https://doi.org/10.1016/j.bcp.2015.07.013
Karamouzis MV, Athanasiadis I, Samelis G, Vallilas C, Bokas A, Nikolaidi A, et al. The impact of thromboprophylaxis on the survival of patients with advanced pancreatic cancer. The pancreatic cancer and tinzaparin (PaCT) study. Cancers (Basel). 2021;13(12):2884.
https://doi.org/10.3390/cancers13122884 DOI: https://doi.org/10.3390/cancers13122884
Auer RC, Ott M, Karanicolas P, Brackstone MR, Ashamalla S, Weaver J, et al. Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. BMJ. 2022;378:e071375.
https://doi.org/10.1136/bmj-2022-071375 DOI: https://doi.org/10.1136/bmj-2022-071375
Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, et al. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018;52(4):1801220.
https://doi.org/10.1183/13993003.01220-2018 DOI: https://doi.org/10.1183/13993003.01220-2018
Regionala Cancer Centrum i Samverkan. Nationellt vårdprogram epitelial äggstockscancer. Version 4.2 [Internet]. In Swedish [cited 2024 Jan 18]. Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/gynekologi/aggstockscancer/nationellt-vardprogram-aggstockscancer.pdf
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9(4):e95192.
https://doi.org/10.1371/journal.pone.0095192 DOI: https://doi.org/10.1371/journal.pone.0095192
Simple Interactive Statistical Analysis. Allocation [Internet]. [cited 2024 January 18]. Available from: https://www.quantitativeskills.com/sisa/.
Chan A-W, Tetzlaff JM, Altman DG, Lauoacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7. DOI: https://doi.org/10.7326/0003-4819-158-3-201302050-00583
Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
https://doi.org/10.1136/bmj.e7586 DOI: https://doi.org/10.1136/bmj.e7586
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Anna Karlsson, Gabriel Lindahl, Anna-Clara Spetz Holm, Karin Bergmark, Pernilla Dahm Kähler, Boglarka Fekete , Ulrika Ottander, Charlotte Öfverman, Pernilla Israelsson, Laila Falknäs, Anders Rosenmüller, Malena Tiefenthal Thrane, Shefqet Halili , Tomas L. Lindahl, Maria C. Jenmalm, Preben Kjølhede
This work is licensed under a Creative Commons Attribution 4.0 International License.
